The Drug Controller General of India authorized the country’s first nasal spray vaccine "under Restricted Use in Emergency Situations for ages 18 and above," marking a big step toward increasing the availability of needle-free vaccines around the world. Washington University St. Louis, which had created and developed the recombinant adenoviral...
Washington Galvanizes as India Battles Covid-19 Tsunami
On April 6, 2020 , as the United States was pummeled by the Covid-19 pandemic, Time Magazine lamented how India had blocked exports of a malaria drug that held potential to treat novel coronavirus patients. The President of the United States tweeted asking India for help and within just six...
India’s Own Covid-19 Vaccine is 81 Percent Effective
Yesterday, Hyderabad-based Bharat Biotech published interim results from the Phase 3 trial of it Covid-19 vaccine, branded as Covaxin. 25,8000 subjects participated in the trial. The trial found 43 cases of COVID-19 patients who showed symptoms ranging from mild to moderate and severe, and of the total cases, 36 were from...
Ocugen licenses India’s Covid-19 Vaccine for U.S use
Pennsylvania-based Ocugen just signed an agreement giving in the rights to the Bharat Biotech Covid-19 vaccine candidate, Covaxin, in the United States. Ocugen will be responsible for clinical development, regulatory approval (including Emergency Use Authorization) and commercialization of this Indian vaccine in America. Covaxin is an advanced stage whole-virion inactivated...
India's Bharat Biotech To Start Phase-1 Trials of Zika Vaccine
After completing pre-clinical studies on its new Zika vaccine candidate Zikavac, Hyderabad, India-based Bharat Biotech announced that the company is now seeking the approval of the government to begin Phase-1 trials where the inactivated vaccine candidate will be tested on 100 people, reports BioSpectrum. India has no known cases of...